Search Medical Condition
Please enter condition
Please choose location

Endometrial Cancer Clinical Trials

A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (183) clinical trials

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian Fallopian Tube Primary Peritoneal or Endometrial Cancer

PRIMARY OBJECTIVES: I. Demonstrate if the combination of letrozole and ribociclib (LEE011) leads to a higher percentage of patients who are progression free at 12 weeks (PFS 12) as compared with that observed in prior studies with single agent letrozole. SECONDARY OBJECTIVES: I. Demonstrate if the combination of letrozole and ...


Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer

PET/MRI has recently become available at the institution and reports of its sensitivity, specificity, NPV (Negative predictive value) , PPV (Positive predictive value), and accuracy in endometrial cancer are not found in the literature to date, to the best of the investigator's knowledge. The GE PET/MRI recently obtained here at ...

Phase N/A

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer

Lynch Syndrome increases an individual's risk for several cancers, such as colorectal, endometrial (EC) and certain types of ovarian cancer (OC). Lynch Syndrome is caused by inherited changes in mismatch repair (MMR) genes. In this study we will establish the proportion of EC and OC patients with Lynch Syndrome. We ...

Phase N/A

DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium Tubes and Ovaries

The vast majority of deaths from ovarian cancer are from the high-grade serous cancer (HGSC) subtypes. The currently available tests for ovarian cancer diagnosis such as, blood tumour marker CA-125 and transvaginal ultrasound scan of the ovaries, have poor sensitivity and specificity therefore are not suitable for diagnosing early disease. ...

Phase N/A

A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion

To determine if Fluorescein systemic injection during hysterectomy procedure can be useful in revealing the depth of endometrial cancer invasion.

Phase N/A

Risk Scoring Model for Endometrial Cancer

A prospective cohort study to assess RHEA ( recurrent vaginal bleeding, hypertension, endometrial thickness and age) scoring model for prediction of endometrial carcinoma

Phase N/A

Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer

Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may ...


Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

PRIMARY OBJECTIVES: I. To determine whether atezolizumab combined with oxaliplatin, leucovorin calcium, and fluorouracil (FOLFOX) and its continuation as monotherapy can significantly improve disease-free survival (DFS) compared to FOLFOX alone in patients with stage III colon cancers and deficient DNA mismatch repair (dMMR). SECONDARY OBJECTIVES: I. To determine whether atezolizumab ...


Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer

PRIMARY OBJECTIVES: I. To determine if there is a decrease in proliferation index, measured by Ki-67 expression, in complex atypical hyperplasia (CAH)/endometrial intraepithelial neoplasia (EIN) or grade 1 endometrial cancer cells from baseline to post-exemestane treatment. SECONDARY OBJECTIVES: I. Circulating serum estradiol and progesterone. II. Pathological response (regression of CAH/EIN ...